Vaccines
Science and Innovation - Animal Health Innovation - Vaccines
Search
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines
Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot
• Boehringer Ingelheim Animal Health Canada Inc. launches a unique vaccine combination that protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv) in one shot
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Does your PRRS vaccine have sufficient “horsepower?”
Does your PRRS vaccine have sufficient “horsepower?”
Reducing PCV2 Viremia in Neonatal Pigs Through Sow Mass Vaccination in an Unstable Herd
Reducing PCV2 Viremia in Neonatal Pigs Through Sow Mass Vaccination in an Unstable Herd
Vaccine protection against different PRRS virus strains
Vaccine protection against different PRRS virus strains
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
Swine
Swine
The Research Process
Science and Innovation - Animal Health Innovation - Parasiticides
Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis
Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis
COVID-19
COVID-19
Equine
Equine
Twenty years of controlling Lawsonia intracellularis
Twenty years of controlling Lawsonia intracellularis
A versatile solution for PCV2 and PRRS protection
A versatile solution for PCV2 and PRRS protection
What large scale economic analyses are saying about Enterisol™ Ileitis
What large scale economic analyses are saying about Enterisol™ Ileitis
Simple and straight to the source: tips for ileitis control
Simple and straight to the source: tips for ileitis control
Salmonella in pigs, pork and people
Salmonella in pigs, pork and people
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
The Hidden Cost of Parasites in Cattle
The Hidden Cost of Parasites in Cattle
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Equine asthma: Recognizing and managing respiratory issues in horses
Equine asthma: Recognizing and managing respiratory issues in horses
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR